Question 1

Is there peer-reviewed research specifically on PEG-MGF (the PEGylated form)?

Accepted Answer

No. A PubMed search for "PEG-MGF"/"PEGylated mechano growth factor" returns no indexed studies of the PEGylated molecule itself. The available preclinical research concerns the unmodified MGF C-terminal E-domain peptide (MGF-Ct24E). The extended-half-life and dosing numbers seen on vendor websites are not supported by peer-reviewed data on this compound and should be treated as unverified. This is Research Use Only information, not medical advice.

Question 2

What is MGF, and how does PEG-MGF relate to it?

Accepted Answer

Mechano growth factor (MGF) is a splice variant of IGF-1 (IGF-1Ec in humans) whose distinct C-terminal "E-domain" can be produced as a short 24-amino-acid synthetic peptide (MGF-Ct24E). "PEG-MGF" refers to that peptide with a polyethylene glycol (PEG) group attached, a chemistry generally intended to slow clearance. Importantly, the biological findings in the literature come from the non-PEGylated peptide; the effect of PEGylation on this specific peptide has not been characterized in indexed studies.

Question 3

What cellular activities have researchers reported for the MGF E-domain peptide in vitro?

Accepted Answer

Cell-culture studies report that the peptide can promote proliferation and migration of muscle precursor cells and mesenchymal stem cells while delaying their differentiation, apparently independent of the classical IGF-1 receptor (Mills 2006, PMID 17156777; Collins 2010, PMID 20875825). These are in vitro observations and do not establish any effect in humans.

Question 4

What does the animal-model evidence show?

Accepted Answer

In rodent and rabbit studies, the unmodified peptide has been investigated in models of muscle-cell transplantation, myocardial infarction, bone-defect repair, and traumatic brain injury, with reports of effects such as improved cell engraftment, reduced cardiomyocyte apoptosis, and enhanced bone-defect repair (e.g., Mills 2007 PMID 17845560; Mavrommatis 2013 PMID 23712705; Deng 2010 PMID 21057789; Liu 2017 PMID 27863093). These are small, early-stage preclinical findings in animals and do not demonstrate safety or efficacy in humans.

Question 5

Are there any human studies of PEG-MGF?

Accepted Answer

No human study has administered MGF E-domain peptide or PEG-MGF. The only human-related data concern endogenous MGF gene expression rising transiently in muscle after resistance exercise or mechanical loading, which is a natural physiological response and is not the same as taking an exogenous peptide.

Question 6

What is known about dosing?

Accepted Answer

There is no established human dosing for this compound. The doses that appear in the literature are from animal models (for example, microgram- to milligram-per-kilogram ranges in rodents and rabbits), and research-reported ranges vary; they do not translate to human use. For any protocol-design questions, consult the referenced primary literature and qualified professionals — this is not medical advice.

Question 7

What is known about safety and observed effects in research?

Accepted Answer

Peer-reviewed safety, toxicology, and pharmacokinetic data for PEG-MGF in humans are not available. Observed effects in research are limited to the preclinical models described above; notably, one mouse cardiac study reported dose-dependent and even opposing functional effects depending on the dose (Solís 2022, PMID 36467694), underscoring that the dose-response behavior is poorly understood. The absence of reported harms in a few small animal studies should not be interpreted as evidence of human safety.

Phase	Daily reference amount	Units / volume
Weeks 1–2	200 mcg	30 units (0.30 mL)
Weeks 3–4	300 mcg	45 units (0.45 mL)
Weeks 5–6	400 mcg	60 units (0.60 mL)
Weeks 7–8	500 mcg	75 units (0.75 mL)

PEG MGF.

Calculated volume reference

Cited protocol & reconstitution guide